Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,127 | -15,106 | -8,772 | -4,232 | -16,306 |
| Depreciation Amortization | 95 | 54 | 21 | 8 | 27 |
| Accounts payable and accrued liabilities | 345 | 141 | 138 | 432 | -205 |
| Other Working Capital | -879 | -1,399 | -3,497 | 73 | 2,114 |
| Other Operating Activity | 1,423 | 1,035 | 615 | -298 | 616 |
| Operating Cash Flow | $-21,143 | $-15,275 | $-11,495 | $-4,017 | $-13,754 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,775 | -674 | -85 | -8 | -211 |
| Investing Cash Flow | $-1,775 | $-674 | $-85 | $-8 | $-211 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 59,900 | 59,893 | 59,892 | N/A | 111 |
| Other Financing Activity | 27,803 | 27,803 | 28,479 | 29,464 | -226 |
| Financing Cash Flow | $87,703 | $87,696 | $88,371 | $29,464 | $-115 |
| Beginning Cash Position | 10,137 | 10,137 | 10,137 | 10,137 | 24,217 |
| End Cash Position | 74,922 | 81,884 | 86,928 | 35,576 | 10,137 |
| Net Cash Flow | $64,785 | $71,747 | $76,791 | $25,439 | $-14,080 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,143 | -15,275 | -11,495 | -4,017 | -13,754 |
| Capital Expenditure | -1,775 | -674 | -85 | -8 | -211 |
| Free Cash Flow | -22,918 | -15,949 | -11,580 | -4,025 | -13,965 |